<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05006521</url>
  </required_header>
  <id_info>
    <org_study_id>KN-002/1/001</org_study_id>
    <nct_id>NCT05006521</nct_id>
  </id_info>
  <brief_title>Single and Multiple Ascending Dose Study of KN-002</brief_title>
  <acronym>KN-002</acronym>
  <official_title>A Phase 1 Randomized, Double-Blinded, Placebo-Controlled, 2-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KN-002 by Inhalation of Single Ascending Doses in Healthy Subjects and Multiple Ascending Doses in Subjects With Stable Mild Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kinaset Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kinaset Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists&#xD;
      of 2 parts: Part 1 is a single ascending dose (SAD) study in healthy volunteers; Part 2 is a&#xD;
      multiple ascending dose (MAD) study in subjects with stable, mild asthma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability (Parts 1 and 2)</measure>
    <time_frame>Day 1 to 17</time_frame>
    <description>To assess the safety and tolerability of KN-002 via the assessment of the number, severity and type of treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Parts 1 and 2)</measure>
    <time_frame>Day 1 to 17</time_frame>
    <description>KN-002 pharmacokinetics after single and repeat dosing: Area under the plasma concentration-time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Parts 1 and 2)</measure>
    <time_frame>Day 1 to 17</time_frame>
    <description>KN-002 pharmacokinetics after single and repeat dosing: Maximum observed plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (Part 2)</measure>
    <time_frame>Day 1 to 17</time_frame>
    <description>Change of fractional exhaled nitric oxide (FeNO) levels after repeated dosing to stable mild asthmatics</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>KN-002 for SAD (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 6 cohorts with 6 of 8 subjects per cohort randomised to receive KN-002</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for SAD (Part 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Up to 6 cohorts with 2 of 8 subjects per cohort randomised to receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KN-002 for MAD (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 4 cohorts with 6 of 8 subjects per cohort randomised to receive KN-002</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for MAD (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 4 cohorts with 2 of 8 subjects per cohort randomised to receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KN-002</intervention_name>
    <description>KN-002 dry powder inhaler</description>
    <arm_group_label>KN-002 for MAD (Part 2)</arm_group_label>
    <arm_group_label>KN-002 for SAD (Part 1)</arm_group_label>
    <arm_group_label>Placebo for MAD (Part 2)</arm_group_label>
    <arm_group_label>Placebo for SAD (Part 1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, 18 - 55 years old&#xD;
&#xD;
          -  Willing and able to give informed consent and comply with the study&#xD;
&#xD;
          -  Body mass index (BMI) 18 to 32 kg/m2 and weighs at least 50 kg&#xD;
&#xD;
          -  Women of child bearing potential must have a negative pregnancy test and use a highly&#xD;
             efficient birth control method&#xD;
&#xD;
          -  Pre-bronchodilator FEV1 ≥ 70 and ≥80% for Part 1 and Part 2 participants, respectively&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant laboratory test abnormalities&#xD;
&#xD;
          -  Clinically significant abnormal blood pressure and/or pulse rate&#xD;
&#xD;
          -  Resting ECG clinically significant abnormalities&#xD;
&#xD;
          -  Respiratory tract infection within 6 weeks of screening&#xD;
&#xD;
          -  Positive test for active COVID-19 within 2 days prior to administration of IMP&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Singh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicines Evaluation Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frazer Morgan</last_name>
    <phone>+44 (0)7841 278534</phone>
    <email>frazer.morgan@kinasettx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Singh</last_name>
      <phone>+44 (0)161 946 1459</phone>
      <email>enquiries@meu.org.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 8, 2021</last_update_submitted>
  <last_update_submitted_qc>August 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Kinaset Therapeutics Inc. will not disclose individual subject de-identified study data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

